Research paper

Smoking cessation and depressive symptoms at 1-, 3-, 6-, and 12-months follow-up

Rubén Rodríguez-Cano a,*, Ana López-Durán a, Elena Fernández del Río a,b, Carmela Martínez-Víspoa, Úrsula Martínez a, Elisardo Becoña a

a Smoking and Addictive Disorders Unit, Faculty of Psychology, Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain
b Department of Psychology and Sociology, Faculty of Social Sciences and Work, University of Zaragoza, Spain

A R T I C L E   I N F O

Article history:
Received 11 August 2015
Received in revised form 18 October 2015
Accepted 23 November 2015

Keywords:
Smoking cessation
Depression
12-months follow-up
Beck Depression Inventory
Relapse

A B S T R A C T

Background: The relationship between tobacco and depressive symptoms has been examined. However, there is little information on the evolution of these symptoms when an individual quits. The aim of this study was to analyze the evolution of depressive symptoms over time (pre-, post-treatment, 1-, 3-, 6-, and 12-months follow-up) in relation to smoking status 12 months after having received a psychological treatment for smoking cessation.

Method: The sample was made up of 242 adults who received cognitive-behavioral treatment for smoking cessation (64.4% women; mean age=41.71 years). The BDI-II was used to assess depressive symptomatology. Participants were classified into three groups according to smoking status at 12-months follow-up (abstainers, relapers, and smokers).

Results: There were no significant differences in depressive symptoms among the three groups at pre-treatment. At the end of treatment, abstainers and relapers presented less depressive symptomatology than smokers. At follow-up, abstainers continued to present less depressive symptomatology than smokers, whereas in relapers, symptoms began to increase as the relapses occurred. Regarding the evolution of depressive symptomatology, the abstainer and relaper groups showed a significant reduction at the end of treatment. Only in the group of abstainers did the decrease continue during 12 months follow-up.

Limitations: The decrease of the initial sample size from 562 to 242 participants. Variables such as self-esteem and self-efficacy were not assessed.

Conclusions: Smoking cessation is associated with a decrease in depressive symptomatology, that is maintained over time. In contrast, relapse is associated with an increase of such symptoms. These findings signify the potential importance of addressing depressive symptomatology in smoking cessation treatment.

© 2015 Published by Elsevier B.V.

1. Introduction

The relationship between tobacco consumption and depression is well established (Tsoh et al., 2000) and has been addressed from multiple perspectives in recent years. People with depression are more likely to be smokers (Breslau et al., 1998; Holma et al., 2013; Lasser et al., 2000) and to be nicotine dependent (Dierker and Donny, 2008). The evidence also indicates that smokers have a higher risk of experiencing depression (Bandiera et al., 2015; Breslau and Johnson, 2000; Grant et al., 2004).

With regard to nicotine withdrawal symptoms, which include some depressive-like symptoms (Hughes, 2007b), findings indicate that smokers with a history of depression are more likely to experience depressive symptoms, and of greater severity, in the withdrawal syndrome (Covey et al., 1990; Langdon et al., 2013). In addition, smokers frequently use tobacco to cope with discomfort that these symptoms cause (Leventhal et al., 2013).

People with depression also have more difficulty quitting smoking (Ziedonis et al., 2008) and are more likely to relapse (Brodker et al., 2014; Zvolensky et al., 2015). In their meta-analysis, Hitsman et al. (2013) found that the existence of a history of major depression in the past, but not in the present, hinders the achievement of abstinence. In addition, evidence suggests that specific symptoms of depression such as anhedonia and low positive affect predict relapse at follow-up (Leventhal et al., 2008).

Please cite this article as: Rodríguez-Cano, R., et al., Smoking cessation and depressive symptoms at 1-, 3-, 6-, and 12-months follow-up. Journal of Affective Disorders (2015), http://dx.doi.org/10.1016/j.jad.2015.11.042
Leventhal et al. (2014) found that life-time anhedonia predicted smoking cessation outcome better than history of depressive disorder and lifetime depressed mood. Further, studies have found that the introduction of cognitive-behavioral mood management techniques significantly improves the effectiveness of smoking cessation interventions (Gierisch et al., 2012). For example, MacPherson et al. (2010), examined the effect of including behavioral activation techniques in a smoking cessation intervention, and found improved abstinence outcomes and decreases in depressive symptomatology.

The findings regarding whether smoking cessation increases the likelihood of depression are inconclusive. Tsoh et al. (2000) found that the likelihood of experiencing depression is similar between those who quit smoking and those who do not, except for those smokers with a previous history of depression, whose risk would be maintained for at least 6 months, according to Glassman et al. (2001). The review by Ragg et al. (2013) indicates that the risk of experiencing depressive symptoms when quitting is not higher in individuals with a history of major depression, because their mood may improve after quitting smoking. Similarly, in a study of smokers with depression, Mathew et al. (2013) found that both those who quit and those who remained abstinent demonstrated significant improvements in psychological functioning compared to those who continued smoking at 3 and 6 months follow-up. The authors note that the increase in depressive symptoms seems to be more closely related to the failure to successfully quit smoking.

In an attempt to explain these discrepancies, Hughes (2007a) notes that the belief that smoking cessation increases depressive symptomatology is due to the attribution that nicotine has antidepressant effects and to the symptomatology associated with the withdrawal syndrome that appears after quitting. However, some research suggests that smokers do not smoke in order to gain the antidepressant effects of smoking and furthermore, depressive symptoms are not the most frequent symptoms when undergoing withdrawal. In fact, with respect to other drugs, the evidence indicates that smoking cessation is related to an improvement of depressive symptoms. Similarly, a recent meta-analysis of longitudinal studies carried out by Taylor et al. (2014) found that both in general and clinical populations (individuals who suffer some mental disorder), smoking cessation is associated with a decrease in depression, anxiety, and stress and an improvement in positive mood and quality of life.

Therefore, the published studies confirm the existence of a clear relationship between smoking and depression, although there are discrepancies between some of the studies about the nature of this relationship and how the variables affect each other. Evaluation of depressive problems at different moments of the process of smoking cessation would help to clarify this relationship, especially taking into account not only the comparison of smokers and abstainers but also including those who initially quit smoking but who relapse later on.

The aim of the present study is to analyze the relationship between depressive symptomatology, assessed with the Beck Depression Inventory-II (BDI-II) at different times (pre-, post-treatment and at 1-, 3-, 6- and 12-months follow-up) and smoking status 12 months after having received a cognitive-behavioral treatment for smoking cessation. To our knowledge, this is the first study that compares depressive symptoms at different times across three groups depending on smoking status at 12 months follow-up: abstainers (those who quit smoking since the end of treatment until 12-months follow-up), smokers (those who never quit smoking), and relapers (those who quit smoking at the end of treatment but who relapsed before the 12-months follow-up). The hypotheses of this study are: (1) people who quit smoking at the end of treatment and remain abstinent at 12 months have fewer depressive symptoms at all the assessed times (pre-, post-treatment and follow-ups) compared to participants who did not quit smoking and those who relapsed, and (2) as the time without smoking increases, people who remain abstinent at 12 months present a greater decrease of depressive symptoms than smokers and relapers at all the evaluations performed.

2. Methods

2.1. Participants

The initial sample consisted of 562 smokers who received cognitive-behavioral treatment for smoking cessation who met the inclusion and exclusion criteria of the study. Inclusion criteria were: aged 18 or over; wishing to participate in the treatment program; and smoking 10 or more cigarettes per day. Exclusion criteria were: a diagnosis of severe mental disorder (bipolar disorder and/or psychotic disorder); concurrent dependence on other substances (alcohol, cannabis, cocaine and/or heroin); having participated in the same or similar treatment over the previous year; having received pharmacological smoking cessation treatment (nicotine replacement therapy, bupropion, varenicline) in the past year; suffering from a physical pathology with a high life risk that would require individual intervention (e.g., recent myocardial infarction); smoking a type of tobacco other than cigarettes (e.g., cigars); and failing to attend the first treatment session. All participants were recruited between 2009 and 2014.

As the aim of this study was to assess depressive symptomatology across all follow-ups, we included only those cases who completed the BDI-II at all times (pre-, post-, and 1-, 3-, 6-, and 12-months follow-up). Therefore, the final sample was made up of 242 smokers.

2.2. Instruments

2.2.1. Smoking Habit Questionnaire

The smokers filled out the 56-item Smoking Habit Questionnaire (Becoña, 1994), designed to gather information both on sociodemographic variables (gender, age, marital status, education level) and tobacco use (i.e., number of cigarettes smoked per day).

2.2.2. Fagerström Test for Nicotine Dependence

(FTND, Heatherton et al., 1991). This scale is made up of 6 items and the scores range from 0 to 10 points. Information related to nicotine dependence was obtained at baseline. In the present sample, the reliability obtained by means of Cronbach’s alpha was 0.59.

2.2.3. Beck Depression Inventory-II

(BDI-II; Beck et al., 1996; Sanz and Vázquez, 2011). This is a 21-item self-report scale measuring current depressive symptoms. The internal consistency obtained in Spanish sample by Cronbach’s alpha was 0.90.

2.2.4. Micro+ Smokerlyzer

(Bedfont Scientific Ltd., Sittingbourne, UK). This was used to measure carbon monoxide (CO) in exhaled air in order to corroborate self-reported abstinence at the end of treatment and at follow-ups (1, 3, 6 and 12 months).

2.3. Procedure

The initial assessment of all smokers was carried out in a face-
to-face interview and the above-described instruments were administered. All the smokers gave their informed consent for participation, and the study was authorized by the Bioethics Committee of the University of Santiago de Compostela. Next, the Smoking Cessation Program (Becolta, 2007), a cognitive-behavioral treatment, was administered in groups of 6–8 participants. This is a standardized and manualized treatment consisting of six sessions (one per week) with the following elements: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control activities, for the avoidance of withdrawal syndrome, physiological feedback (CO in exhaled air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies.

There was a face-to-face follow-up 1, 3, 6, and 12 months after treatment. Self-reported abstinence at the end of treatment and at each follow up was assessed by CO in exhaled air (CO<10 ppm). Biochemically validated smoking status was used rather than self-reported smoking status. Participants did not use pharmacological smoking cessation treatment during the Smoking Cessation Program or during follow-up. The criteria used for point-prevalence abstinence at the end of treatment was not smoking in the past 24 h; at 1 and 3 months follow-up point prevalence abstinence was defined as not smoking in the past 7 days and at 6 and 12 months follow-up not smoking in the past 30 days. A participant presenting continuous abstinence at the 12-months follow-up (not having smoked, not even a puff since the end of treatment) was considered to belong to the abstainer group. Those who did not quit smoking at the end of treatment and continued smoking during the follow-ups were considered smokers, and those who stopped smoking at the end of the treatment but were smoking during follow-up were considered relapsers (West et al., 2005).

### 2.4. Statistical analysis

To examine possible differences as a function of smoking status at 12 months (smokers, relapsers, and abstainers) in demographic and tobacco consumption variables and pretreatment depressive symptomatology, we used chi-square and Snedecor’s F. To determine the effect size, we used Cramer’s V and eta-square, respectively.

Mean scores in depressive symptoms were compared among the three groups, smokers, relapsers, and abstainers, at all times (pre- and posttreatment and of 1-, 3-, 6- and 12-months follow-ups) and a one factor ANOVA was carried out. For post hoc comparisons, we used the Bonferroni method. To correct the absence of homoscedasticity, we applied a correction of F (Brown–Forsythe F – Brown and Forsythe, 1974). For post hoc analysis of the Brown–Forsythe F, we used Games–Howell’s method (Games and Howell, 1976).

To assess longitudinal changes in depressive symptoms within subjects in each of the three groups, we used a repeated measures ANOVA. The repeated measures factor was the BDI-II score at pre- and posttreatment and at 1-, 3-, 6- and 12-months follow-up. We used the Greenhouse–Geisser F (F(2,2)) to correct for the absence of sphericity, in order to accommodate more general covariance structures for the repeated measures (Greenhouse and Geisser, 1959). Post hoc analyses were performed with the Bonferroni test.

Analyses were performed with the SPSS 20, and the statistical significance level was set at ≤0.05.

### 3. Results

The average age of participants was 41.71 years (SD=10.11); 37.6% of the sample were male and 62.4% female. The average number of cigarettes smoked per day was 20.57 (SD=7.11); 41.7% had higher education and more than one half (55%) were married or living as a couple. The mean nicotine dependence score (according to the Fagerström Test for Nicotine Dependence – FTND) was 5.13 (SD=2.08).

At the end of treatment, 79.8% of the participants (N=242) had quit smoking. For this study, we divided the sample into three groups, as a function of the participants’ smoking status at 12 months: smokers (n=49), abstainers (n=91), and relapers (n=102). Fifty-two percent (n=53) of participants in the relaper group had relapsed before the 3-month follow-up.

We found no significant differences as a function of socio-demographic characteristics (age, gender, marital status, and level of education) or in pretreatment BDI-II scores among the three groups. We found significant differences at pretreatment between

### Table 1

Demographics, smoking history, and depression variables at pretreatment among smoking status groups at 12 months (N=242).

<table>
<thead>
<tr>
<th></th>
<th>Smokers (n=49)</th>
<th>Relapsers (n=102)</th>
<th>Abstainers (n=91)</th>
<th>χ²</th>
<th>p</th>
<th>Cramer’s V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>29</td>
<td>65</td>
<td>63.7</td>
<td>57</td>
<td>62.6</td>
<td>0.295</td>
</tr>
<tr>
<td>Male</td>
<td>20</td>
<td>37</td>
<td>36.3</td>
<td>34</td>
<td>37.4</td>
<td>0.863</td>
</tr>
<tr>
<td>Marital Status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.035</td>
</tr>
<tr>
<td>Single</td>
<td>15</td>
<td>39</td>
<td>38.3</td>
<td>28</td>
<td>30.8</td>
<td>3.020</td>
</tr>
<tr>
<td>Married</td>
<td>29</td>
<td>50</td>
<td>49</td>
<td>54</td>
<td>59.3</td>
<td>0.806</td>
</tr>
<tr>
<td>Divorced</td>
<td>4</td>
<td>8.2</td>
<td>9.8</td>
<td>8</td>
<td>8.8</td>
<td>0.079</td>
</tr>
<tr>
<td>Widowed</td>
<td>1</td>
<td>2</td>
<td>2.9</td>
<td>1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Educational Level</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>12</td>
<td>24.5</td>
<td>21.6</td>
<td>22</td>
<td>24.2</td>
<td>5.996</td>
</tr>
<tr>
<td>Middle</td>
<td>23</td>
<td>46.9</td>
<td>35.3</td>
<td>26</td>
<td>28.6</td>
<td>7.115*</td>
</tr>
<tr>
<td>Higher</td>
<td>14</td>
<td>28.6</td>
<td>43.1</td>
<td>43</td>
<td>47.2</td>
<td>0.029</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.171</td>
</tr>
<tr>
<td>M</td>
<td>43.86</td>
<td>8.85</td>
<td>42.04</td>
<td>40.20</td>
<td>8.95</td>
<td>7.115*</td>
</tr>
<tr>
<td>SD</td>
<td>11.44</td>
<td>123.04</td>
<td></td>
<td>31</td>
<td>34.1</td>
<td>3.020</td>
</tr>
<tr>
<td>CPD</td>
<td>23</td>
<td>7.90</td>
<td>20.73</td>
<td>19.08</td>
<td>6.80</td>
<td></td>
</tr>
<tr>
<td>BDI-II pre-treat.</td>
<td>13.12</td>
<td>11.31</td>
<td>9.45</td>
<td>9.33</td>
<td>10.27</td>
<td>4.732a</td>
</tr>
</tbody>
</table>

Note. FTND: Fagerström Test for Nicotine Dependence; CPD: Cigarettes Per Day; BDI-II: Beck Depression Inventory II.

* Significant intergroup differences between Abstainers and Smokers.
abstainers and smokers in the FTND ($\chi^2 = 7.115, p < .05$) and the number of cigarettes/day pretreatment ($F = 4.732, p < 0.01$) (see Table 1).

3.1. Smoking status at the 12-months follow-up and depression across time (pre- and posttreatment and follow-ups)

As shown in Table 2, abstainers had a lower BDI-II score at the end of treatment and at all follow-ups than smokers. Abstainers also presented fewer depressive symptoms than relapers, but only at the 3-, 6-, and 12-months follow-ups. Additionally, we also found that the relaper group scored significantly lower in the BDI-II than the smokers at the end of treatment and at 6-month follow-up.

3.2. Evolution of depression from pretreatment to 12-months follow-up

Regarding the evolution of depressive symptomatology, the repeated measures analysis yielded differences in depressive symptoms over time as a function of smoking status at 12 months ($F_{(6,1,032.80)} = 3.205, p = 0.001, \eta^2 = 0.026$), adjusting for nicotine dependence ($F_{(6,1,032.80)} = 0.05$). Therefore, the means presented within the group are estimated means after including these covariates (see Fig. 1).

Post-hoc comparisons show that the abstainers’ group was the only one that presented significant differences at the end of treatment and at all follow-ups in comparison to pretreatment assessment. As time went by without smoking, their depressive symptomatology decreased, and the most important reduction occurred at the 3-month follow-up (5.04 marginal points) compared to the pretreatment assessment.

The group of relapers only presented significant differences between the pre- and post-treatment assessments. As soon as they quit smoking, the depressive symptoms decreased, but these differences disappeared when relapses occurred. In the group of smokers there were no significant differences in depressive symptomatology either at the initial level, at the end of treatment, or at follow-up.

4. Discussion

The present study aimed to analyze the relationship between the evolution of depressive symptoms and smoking status at 12 months follow-up in smokers who received a cognitive-behavioral treatment for smoking cessation. The presence of depressive symptoms as measured with the BDI-II was assessed at different times (pre-, post-treatment, and at 1-, 3-, 6-, and 12-months follow-ups).

Differences in terms of sociodemographic characteristics (age, gender, marital status and level of education) among the three groups were not found. Berlin et al. (2010) did not find differences between abstinent and smokers in age, gender and depression at baseline characteristics either. In reference to depressive symptoms scores, we have not reached differences in the BDI-II scores at baseline. In this sense, Kahler et al. (2002) showed that smokers who were abstinent had lower BDI-II scores at baseline than smokers however, they also concluded that giving up smoking provokes a decrease in depressive symptoms.

The first hypothesis, that people who quit smoking and remain abstinent at 12 months have fewer depressive symptoms at all assessment times was partially supported.

The results showed that the group of abstainers had fewer depressive symptoms than the other two groups at all times analyzed, except for the pretreatment assessment, where we found no significant differences. That is, the depressive symptoms they presented when initiating the smoking cessation treatment did not determine treatment success either at the short or the long term. Previous studies suggesting that people with depression have more difficulty quitting and a higher likelihood of relapse (i.e., Ziedonis et al., 2008; Zvolensky et al., 2015). Also, Leventhal et al. (2014) showed that lifetime depressive symptoms are associated with continuing to smoke. There may be other variables such as the existence of a history of depression in the past, as indicated by Hitsman et al. (2013), which determine treatment outcome, so that the presence of this type of symptoms should not be an obstacle for people to start a smoking cessation treatment and to succeed in it.

In the remaining evaluations (post-treatment and follow-ups), people who quit smoking and remained abstinent at 12 months had significantly lower scores in depressive symptomatology compared to the remaining groups.

![Fig. 1](https://example.com/fig1.png)

**Fig. 1.** Estimated means in depression (BDI-II) according to time and smoking status at 12 months, adjusting for nicotine dependence (N=242).
compared with people who did not quit smoking. In a sample of patients with chronic depressive disorder, Matthew et al. (2013) found that smokers who achieved prolonged abstinence showed decreased levels of affective symptoms at 6 months follow up. Therefore, quitting smoking may be associated with improvements in mood (Taylor et al., 2014) or at the very least does not result in an increase in depressive symptoms Capron et al. (2014).

Conversely, previous studies show that depressive symptoms increase after quitting smoking due to the loss of the antidepressant effects of nicotine or to nicotine withdrawal (Hughes, 2007b).

Another outcome that supports the importance of smoking cessation for mood improvement is that the relapser group increased their scores in depression in comparison with the group of abstainers as of the 3-month follow-up (up to that time, the scores were similar). This period has been shown as the most likely for smoking relapse (Piñeiro et al., 2014). Berlin et al. (2010) showed that smokers who relapse exhibited an increase in depression and anxiety symptoms, as well as suicidal ideation. As pointed out by Zvolensky et al. (2015), further investigations must examine whether the increase in depressive symptoms leads to relapse or whether, on the contrary, after a relapse there is an increase in depressive symptoms due to, for example, reduction of self-efficacy.

The results of this study support the second hypothesis. In the group that remained abstinent at 12 months follow-up, there was a gradual decrease of depressive symptomatology from pretreatment until the 12 months follow-up. In the groups of smokers and relapers, only at the end of treatment was there an improvement of symptoms. This decrease produced during treatment in all the groups might be due to the fact that the treatment includes psychological strategies that may also be useful for mood management (e.g., problem solving, stress management), but after completing the treatment or if there is a relapse, these positive effects on mood disappear. Ischaki and Gratziou (2009) and Brodbeck et al. (2014) point to self-efficacy and self-esteem as mediating variables between depression and smoking cessation. Compared with relapers or with those who never stopped smoking, those who remain abstinent—despite not differing in depression scores at the beginning of treatment—probably use the strategies to maintain abstinence that they learned throughout the treatment, thereby increasing their self-efficacy and the likelihood of not relapsing (Marlatt and Donovan, 2005).

This study allows us to conclude that people who quit smoking by means of a cognitive behavioral treatment present a decrease in depressive symptomatology that is maintained if they do not relapse. The mood management strategies that are used in the treatment may be decisive, not only to increase the probability of smoking cessation but also to improve mood; hence, the importance of including them in treatments regardless of whether or not depression is present (Brown et al., 2001; Haas et al., 2004; MacPherson et al., 2010). Even though in the current study, the mean depression scores within the group of abstainers are within the normal range at pretreatment and 12 months follow up, previous studies including Lenaenthal et al. (2014) and Niaura et al. (2001) have shown that lower level depressive symptoms can predict treatment outcomes. For this reason our results have a clinical significance for smoking treatment. Therefore, we can also conclude that smoking cessation is recommended even in those people who were previously thought to have difficulties due to presenting depressive problems.

4.1. Limitations and future directions

Among the limitations of the present study, we highlight the decrease of the initial sample size from 562 to 242 participants, as we could only use those smokers of whom we had BDI-II data at all the assessment times. However, we point out that this is the first study to perform an assessment of depressive symptoms at different key periods of the cessation process and during the period of greatest risk of relapse. A second limitation is that variables such as self-esteem and self-efficacy were not assessed within the current study. These variables could be relevant in explaining the relationship between depression and smoking cessation. However, as noted above, this opens new lines of research to continue working.

Among the strengths of this study, we note that, in addition to performing an assessment of the evolution of depressive symptoms, we took into account not only the group of abstainers and the group of smokers but also a group of the people who relapsed after quitting. In addition, we used the most restrictive abstinence criterion, continuous abstinence, which allows more accurate interpretation of the results obtained (West et al., 2005).

As stated by Berlin et al. (2009), the relationship between smoking cessation and depression is complex. Further studies conducted with people with past or current symptoms of depression are needed as there are few studies within this area (Weinberger et al., 2013). This study provides useful information on what occurs after treatment and at follow-up regarding the evolution of depressive symptoms and the benefits that smoking cessation may have on mood.

Contributors

EB, AL, EFR, RRC, CM and UM designed the study and wrote the protocol. RRC, ALD, EFR, CM, UM and EB obtained the data. RRC, EB, AN and EFR conducted the statistical analysis and contributed to the interpretation of the data. RRC, EB, ALD, EFR drafted the manuscript. CM, UM provided feedback. All authors contributed to and have approved the final manuscript.

Declaration of interests

There are none.

Acknowledgments

This research was supported by the Spanish Ministerio de Ciencia y Competitividad (Project reference: P12012-31196) and by FEDER (European Regional Development Fund).

References


Psychiatry 55, 161–166.


